SCHEMBL15035862

SCHEMBL15035862

C#Cc1cc2cnc(Nc3ccc(NC4CCN(C)C4)cc3)nc2n(Cc2ocnc2[S+]([O-])CCN(C)C)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.35
JAK3 P52333 6/20 0.35
FGFR1 P11362 5/20 0.34
PIK3CD O00329 1/20 0.34
PRKAB2 O43741 1/20 0.34
NUAK1 O60285 1/20 0.34
CCNT1 O60563 1/20 0.34
ABL1 P00519 1/20 0.34
FYN P06241 1/20 0.34
CDK1 P06493 1/20 0.34
CSF1R P07333 1/20 0.34
RET P07949 1/20 0.34
PDGFRB P09619 1/20 0.34
CDK4 P11802 1/20 0.34
CCNB1 P14635 1/20 0.34
CCNA2 P20248 1/20 0.34
CCND1 P24385 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
MARK3 P27448 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15041626 0.94 NUAK1 (0.41) JAK3FGFR1PIK3CDPRKAB2NUAK1
SCHEMBL15035778 0.79 CDK4 (0.36) JAK3FGFR1PIK3CDPRKAB2NUAK1
SCHEMBL15034874 0.78 CDK4 (0.38) JAK3FGFR1PIK3CDPRKAB2NUAK1
SCHEMBL15035639 0.77 JAK3 (0.37) JAK3FGFR1PIK3CDPRKAB2NUAK1
SCHEMBL15277167 0.73 TNK2 (0.39) SRCJAK3FGFR1TNK2
SCHEMBL15041421 0.72 NUAK1 (0.43) JAK3FGFR1PIK3CDPRKAB2NUAK1
SCHEMBL15034955 0.71 JAK3 (0.37) SRCJAK3FGFR1PIK3CDPRKAB2
SCHEMBL15034774 0.71 CDK4 (0.37) JAK3FGFR1PIK3CDPRKAB2NUAK1
SCHEMBL15034977 0.71 FGFR1 (0.37) JAK3FGFR1PIK3CDPRKAB2NUAK1
SCHEMBL15041418 0.71 TNK2 (0.38) SRCJAK3FGFR1CDK4CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK6 SRC 361/4885JAK3 525/4885FGFR1 2209/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 SRC 26/4885JAK3 1901/4885FGFR1 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.